{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-208282","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2024-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.100763+00:00","generated_at":"2026-05-31T07:19:23.003487+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Delcath reports positive results from two independent studies on CHEMOSAT and HEPZATO KIT in liver cancers","bullets":["CHEMOSAT study: 91% disease control rate, 18.2% complete response in liver tumors; median hepatic PFS 52 weeks overall.","CHEMOSAT in uveal melanoma: median hepatic PFS 69 weeks; in cholangiocarcinoma: 38 weeks.","HEPZATO KIT first-line: median OS 22.4 months, hepatic PFS 17.6 months vs 8.8 months for immunotherapy.","HEPZATO KIT second-line: median PFS 22.2 months; hepatic PFS not reached vs 14.7 months for immunotherapy.","Both studies published in peer-reviewed journals (ESMO GI and Annals of Surgical Oncology)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-208282","json":"https://secwatch.observer/filing/0001193125-24-208282.json","markdown":"https://secwatch.observer/filing/0001193125-24-208282.md","text":"https://secwatch.observer/filing/0001193125-24-208282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000119312524208282/0001193125-24-208282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000119312524208282/d848260d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:19:23.003487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}